

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Madsen Julia</u> (Last) (First) (Middle) <u>C/O 70 SIR JOHN ROGERSON'S QUAY</u> (Street) <u>DUBLIN L2 2</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>STERIS plc [STE]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Senior VP, Life Sciences</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/31/2024</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	05/31/2024		F		207 ⁽¹⁾	D	\$222.88	8,344 ⁽²⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

- 207 shares were withheld from the 578 restricted shares that vested on May 31, 2024. These 207 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 578 ordinary shares were awarded to Ms. Madsen on May 31, 2023. These vested shares were valued at the NYSE closing market price on May 31, 2024.
- As of May 31, 2024, 3,692 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 352 on June 3, 2024; 123 on June 3, 2024; 360 on June 3, 2024; 349 on October 1, 2024; 144 on October 1, 2024; 578 on June 2, 2025; 352 on June 2, 2025; 360 on June 2, 2025; 144 on October 1, 2025; 578 on June 1, 2026 and 352 on June 2, 2026.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Ronald E. Snyder, Authorized Representative under Power of Attorney

06/04/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Securities and Exchange Commission
Washington, D.C. 20549

RE: STERIS plc
1933 Act and 1934 Act Filings
Authorized Representatives

Ladies and Gentlemen:

The above Company, a public limited company organized under the laws of Ireland, is the issuer of securities registered under Section 12 of the Securities Exchange Act of 1934. The undersigned confirms, as of the date appearing opposite his/her signature, that each of the "Authorized Representatives" named below is authorized on his/her behalf to sign such statements (on Form 3, Form 4, Form 5, Form 144, Schedule 13G, Form ID (if necessary) or otherwise, collectively, "Forms") with respect to securities of the Company (the "Securities"), and to submit to the Securities and Exchange Commission such Forms (including reports, notices, and other statements) with respect to the Securities, as are required by the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934 as amended (collectively, the "Acts"). The undersigned also confirms the authority of each of the Authorized Representatives to do and perform, on his/her behalf, any and all acts and things with respect to the Securities requisite or necessary to ensure compliance by the undersigned with the filing requirements of the Acts.

This authority revokes all prior authorities with respect to the Securities previously executed by the undersigned including but not limited to any such authorities filed with or given to the Commission by the undersigned. This authority contained herein shall remain in full force and effect until the undersigned is no longer required to file Forms with respect to the undersigned's holdings of and transactions in the Securities, unless earlier revoked by the undersigned in a signed writing delivered to the Authorized Representatives.

Authorized Representatives

Monika T. Barrios
Rebecca A. Nichols
Ronald E. Snyder
Michael J. Tokich
John P. Ubbing
J. Adam Zangerle

The undersigned acknowledges that the foregoing Authorized Representatives, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with the Acts. Additionally, although pursuant to this authority, the Authorized Representatives will use commercially reasonable efforts to timely and

accurately file the required Forms on behalf of the undersigned, the Authorized Representatives do not represent or warrant that they will be able to in all cases timely and accurately file such Forms on behalf of the undersigned due to various factors and the undersigned and the Authorized Representatives' need to rely on others for information, including the undersigned and brokers of the undersigned.

Dated: October 31, 2023

By: /s/ Julia Madsen
Signature

Julia Madsen
Printed Name
